Kory James Wentworth sold $173k of TRDA
Chief Financial Officer at Entrada Therapeutics, Inc.. 8,637 shares at an average of $19.98, traded Nov 11, 2024, filed Nov 13, 2024.
Score components
- +22RoleCFO
- +11Trade size$173k at market
- +5Share of holdings soldSold 10% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -11.5%, 3m -36.4%, 6m -60.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001689375-24-000065, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 11, 2024 | MOption exercise Common Stock10b5-1 | +6,000 | $2.10 | $13k | 82,486 | Nov 13, 2024 |
| Nov 11, 2024 | SOpen-market sale Common Stock10b5-1 | -8,637 | $19.98 | $173k | 73,849 | Nov 13, 2024 |
| Nov 11, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -6,000 | $0.00 | $0 | 37,157 | Nov 13, 2024 |
Related signals
Other insiders at Entrada Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $1.9M 259,837 shares | -6% | |
| 45Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $1.9M 259,837 shares | -6% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $617k 86,482 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $616k 86,914 shares | -2% | |
| 40Moderate | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $616k 86,914 shares | -2% | |
| 37Weak | Entrada Therapeutics, Inc. | MPM BioVentures 2014, L.P. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | Mpm Bioventures 2018, L.p. owner | $462k 62,714 shares | -1% | |
| 37Weak | Entrada Therapeutics, Inc. | 5AM Ventures V, L.P. owner | $432k 62,811 shares | -2% | |
| 48Moderate | Entrada Therapeutics, Inc. | Kush Parmar director | $1.1M 155,255 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.